Bock, Hans-Christoph

[["dc.bibliographiccitation.firstpage","441"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurosurgical Review"],["dc.bibliographiccitation.lastpage","449"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Puchner, Maximilian Josef Anton"],["dc.contributor.author","Lohmann, Frauke"],["dc.contributor.author","Schuetze, Michael"],["dc.contributor.author","Koll, Simone"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Buchalla, Ruediger"],["dc.contributor.author","Rainov, Nikolai"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:38:45Z"],["dc.date.available","2018-11-07T08:38:45Z"],["dc.date.issued","2010"],["dc.description.abstract","Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. But these studies and subsequent non-phase III studies have also shown risks associated with local chemotherapy within the central nervous system. The introduction of concomitant radiochemotherapy with temozolomide (TMZ) has later demonstrated a survival benefit in a phase III trial and has become the current treatment standard for newly diagnosed malignant glioma patients. Lately, this has resulted in clinical protocols combining local chemotherapy with BCNU wafers and concomitant radiochemotherapy with TMZ although this may carry the risk of increased toxicity. We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy. We have retrospectively analyzed the postoperative clinical course, occurrence and severity of adverse events, progression-free interval, and overall survival in 44 patients with newly diagnosed glioblastoma multiforme. All patients received multimodal treatment including tumor resection, BCNU wafer implantation, and concomitant radiochemotherapy. Of 44 patients (mean age 59 +/- 10.8 years) with glioblastoma who received Gliadel wafer at primary surgery, 28 patients (64%) had died, 16 patients (36%) were alive, and 15 patients showed no evidence of clinical or radiographic progression after a median follow-up of 15.6 months. At time of analysis of adverse events in this patient population, the median overall survival was 12.7 months and median progression-free survival was 7.0 months. Surgical, neurological, and medical adverse events were analyzed. Twenty-three patients (52%) experienced adverse events of any kind including complications that did not require treatment. Nineteen patients (43%) experienced grade 3 or grade 4 adverse events. Surgical complications included cerebral edema, healing abnormalities, cerebral spinal fluid leakage, meningitis, intracranial abscess, and hydrocephalus. Neurological adverse events included newly diagnosed seizures, alteration of mental status, and new neurological deficits. Medical complications were thromboembolic events (thrombosis, pulmonary embolism) and hematotoxicity. Combination of both treatment strategies, local chemotherapy with BCNU wafer and concomitant radiochemotherapy, appears attractive in aggressive multimodal treatment schedules and may utilize the sensitizing effect of TMZ and carmustine on MGMT and AGT on their respective drug resistance genes. Our data demonstrate that combination of local chemotherapy and concomitant radiochemotherapy carries a significant risk of toxicity that currently appears underestimated. Adverse events observed in this study appear similar to complication rates published in the phase III trials for BCNU wafer implantation followed by radiation therapy alone, but further add the toxicity of concomitant radiochemotherapy with systemic TMZ. Save use of a combined approach will require specific prevention strategies for multimodal treatments."],["dc.identifier.doi","10.1007/s10143-010-0280-7"],["dc.identifier.isi","000282843600013"],["dc.identifier.pmid","20706757"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18832"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0344-5607"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.contributor.author","Bettag, Christoph"],["dc.contributor.author","Hussein, Abdelhalim"],["dc.contributor.author","Sachkova, Alexandra"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Abboud, Tammam"],["dc.date.accessioned","2021-07-05T15:00:56Z"],["dc.date.available","2021-07-05T15:00:56Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s11060-021-03792-w"],["dc.identifier.pii","3792"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87939"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.relation.eissn","1573-7373"],["dc.relation.issn","0167-594X"],["dc.title","Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","655"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","661"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Siam, Laila"],["dc.contributor.author","Larsen, Joerg"],["dc.contributor.author","Burger, Ralf"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Bockermann, Volker"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:44:14Z"],["dc.date.available","2018-11-07T08:44:14Z"],["dc.date.issued","2010"],["dc.description.abstract","In contrast to other regions of the human spine, dorsal fixation with rods and pedicle screws is comparatively rarely performed in the cervical spine. Although this technique provides a higher mechanical strength than the more frequently used lateral mass screws, many surgeons fear the relatively high rate of misplacements. This higher incidence is mainly due to the complex vertebral anatomy in this spinal segment. For correct screw placement, the availability of an immediate and efficient intra-operative imaging tool to ascertain the accuracy of the pedicle screw hole position would be beneficial. We have previously investigated the usefulness of an intraspinal, specifically, intra-osseous ultrasound technique in the lumbar spine. In this study its accuracy as a means of controlling intrapedicular screw hole positioning has been evaluated in the cervical spine. An endovascular ultrasound transducer was used for the intra-luminal scanning of 54 pedicle screw holes in cadaveric human spine specimens. Twenty-three of these had been intentionally misplaced (cortex breached). The resulting image files were assessed by three investigators blinded to both the procedure and the corresponding CT findings. The investigators differentiated correctly between adequately and poorly placed pedicle screw holes in 96% of cases. False negatives and false positives both occurred in no more than 1.8% of cases. Intrapedicular ultrasonography of pedicle screw holes in the cervical spine is a promising technique for the intra-operative assessment of bore hole placement and may increase operative safety and postoperative outcome in posterior cervical fusion surgery."],["dc.identifier.doi","10.1007/s00701-009-0447-6"],["dc.identifier.isi","000275945600013"],["dc.identifier.pmid","19597760"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4182"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20152"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0001-6268"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intra-osseous ultrasound for pedicle screw positioning in the subaxial cervical spine: an experimental study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","252"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neurosurgery"],["dc.bibliographiccitation.lastpage","262"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Thomale, Ulrich-Wilhelm"],["dc.contributor.author","Schaumann, Andreas"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Giese, Henrik"],["dc.contributor.author","Schuster, Dhani"],["dc.contributor.author","Kästner, Stefanie"],["dc.contributor.author","Ahmadi, Sebastian A."],["dc.contributor.author","Polemikos, Manolis"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Gölz, Leonie"],["dc.contributor.author","Lemcke, Johannes"],["dc.contributor.author","Hermann, Elvis"],["dc.contributor.author","Schuhmann, Martin"],["dc.contributor.author","Beez, Thomas"],["dc.contributor.author","Fritsch, Michael"],["dc.contributor.author","Orakcioglu, Berk"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Bohner, Georg"],["dc.date.accessioned","2018-10-10T07:14:06Z"],["dc.date.available","2018-10-10T07:14:06Z"],["dc.date.issued","2018-08-01"],["dc.description.abstract","Freehand ventricular catheter placement may represent limited accuracy for the surgeon's intent to achieve primary optimal catheter position.To investigate the accuracy of a ventricular catheter guide assisted by a simple mobile health application (mhealth app) in a multicenter, randomized, controlled, simple blinded study (GAVCA study). In total, 139 eligible patients were enrolled in 9 centers. Catheter placement was evaluated by 3 different components: number of ventricular cannulation attempts, a grading scale, and the anatomical position of the catheter tip. The primary endpoint was the rate of primary cannulation of grade I catheter position in the ipsilateral ventricle. The secondary endpoints were rate of intraventricular position of the catheter's perforations, early ventricular catheter failure, and complications. The primary endpoint was reached in 70% of the guided group vs 56.5% (freehand group; odds ratio 1.79, 95% confidence interval 0.89-3.61). The primary successful puncture rate was 100% vs 91.3% (P = .012). Catheter perforations were located completely inside the ventricle in 81.4% (guided group) and 65.2% (freehand group; odds ratio 2.34, 95% confidence interval 1.07-5.1). No differences occurred in early ventricular catheter failure, complication rate, duration of surgery, or hospital stay. The guided ventricular catheter application proved to be a safe and simple method. The primary endpoint revealed a nonsignificant improvement of optimal catheter placement among the groups. Long-term follow-up is necessary in order to evaluate differences in catheter survival among shunted patients."],["dc.fs.pkfprnr","44523"],["dc.identifier.doi","10.1093/neuros/nyx420"],["dc.identifier.fs","633504"],["dc.identifier.pmid","28973670"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15918"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1524-4040"],["dc.title","GAVCA Study: Randomized, Multicenter Trial to Evaluate the Quality of Ventricular Catheter Placement with a Mobile Health Assisted Guidance Technique"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","199"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","CENTRAL EUROPEAN NEUROSURGERY"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","71"],["dc.contributor.author","Giese, A."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Rohde, Veit"],["dc.date.accessioned","2018-11-07T08:37:23Z"],["dc.date.available","2018-11-07T08:37:23Z"],["dc.date.issued","2010"],["dc.description.abstract","Implantation of BCNU wafers (Gliadel (R)) into the resection cavity has demonstrated a survival benefit for patients with newly diagnosed malignant gliomas. The follow-up of two phase III trails has further shown that the number of long-term survivors was significantly increased by BCNU wafer treatment. BCNU wafer implantation may be integrated into current multimodal first line strategies. In the setting of recurrent disease BCNU wafer implantation has also shown a survival benefit and now extends the treatment options in a patient population that typically has undergone extensive pretreatment. An analysis of the literature has helped to clearly identify the risks associated with topic BCNU treatment. Here we summarize the incidence and time course of adverse events associated with local chemotherapy and propose solutions. The growing body of experience with BCNU wafer implantation may serve as a basis to develop adequate risk management strategies with regard to patient selection, surgical techniques, and follow-up schedules."],["dc.identifier.doi","10.1055/s-0029-1242775"],["dc.identifier.isi","000284355500007"],["dc.identifier.pmid","20063259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18516"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0044-4251"],["dc.title","Risk Management in the Treatment of Malignant Gliomas with BCNU Wafer Implants"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Rohde, Veit"],["dc.date.accessioned","2018-11-07T11:21:42Z"],["dc.date.available","2018-11-07T11:21:42Z"],["dc.date.issued","2009"],["dc.format.extent","950"],["dc.identifier.isi","000272974100347"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55836"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.conference","3rd Quadrennial Meeting of the World-Federation-of-Neuro-Oncoloyg/6th Meeting of the Asian-Society-for-Neuro-Oncology"],["dc.relation.eventlocation","Yokohama, JAPAN"],["dc.relation.issn","1522-8517"],["dc.title","SAFETY PROFILE OF CARMUSTINE WAFER TREATMENT IN FIRST-LINE TREATMENT OF MALIGNANT GLIOMA WITH CARMUSTINE IMPLANTS FOLLOWED BY CONCOMITANT RADIOCHEMOTHERAPY"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2142"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Clinical Neurology and Neurosurgery"],["dc.bibliographiccitation.lastpage","2146"],["dc.bibliographiccitation.volume","115"],["dc.contributor.author","Behm, Timo"],["dc.contributor.author","Horowski, Antonia"],["dc.contributor.author","Schneider, Simon"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Stockhammer, Florian"],["dc.date.accessioned","2018-11-07T09:19:20Z"],["dc.date.available","2018-11-07T09:19:20Z"],["dc.date.issued","2013"],["dc.description.abstract","Objective: The effect of concomitant and adjuvant temozolomide in glioblastoma patients above the age of 65 years lacks evidence. However, after combined treatment became standard at our center all patients were considered for combined therapy. We retrospectively analyzed the effect of temozolomide focused on elderly patients. Methods: 293 patients with newly diagnosed glioblastoma treated single-centered between 1998 and 2010, by radiation alone or concomitant and adjuvant radiochemotherapy, were included. Treatment groups were analyzed by multi- and univariate analysis. Matched pairs for age, by a 5-year-caliper, extent of resection and general state was generated for all patients and elderly subgroups. Results: 103 patients received radiation only and 190 combined treatment. Multivariate and matched pair analysis revealed a benefit due to combined temozolomide (HR 1.895 and 1.752, respectively). For patients older than 65 years median survival was 3.6 (95% CI 3.2-4.7) and 8.7 months (6.3-11.8) for radiotherapy only and combined treatment (HR 3.097, p < 0.0001, n = 90). Over the age of 70 and 75 years median survival was 3.2 (2.3-4.2) vs. 7.5 (5.1-10.9, HR 4.453, p < 0.0001, n = 62) and 3.2 (1.4-3.9) vs. 9.2 months (4.7-13.5; HR 9.037, p < 0.0001, n = 24), respectively. In 8/56 (14%) patients over the age of 70 years temozolomide was terminated due to toxicity. Conclusion: Retrospective matched pair analysis gives class 2b evidence for prolonged survival due to concomitant and adjuvant temozolomide in elderly glioblastoma patients. Until prospective data for combined radiochemotherapy in elderly patients will be available concomitant and adjuvant temozolomide therapy should not be withheld. (C) 2013 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.clineuro.2013.08.002"],["dc.identifier.isi","000325833200038"],["dc.identifier.pmid","23993314"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28606"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1872-6968"],["dc.relation.issn","0303-8467"],["dc.title","Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","63"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","70"],["dc.bibliographiccitation.volume","159"],["dc.contributor.author","von Eckardstein, Kajetan L."],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Psychogios, Marios-Nikos"],["dc.contributor.author","Schatlo, Bawarjan"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ludwig, Hans Christoph"],["dc.contributor.author","Bock, Hans Christoph"],["dc.date.accessioned","2018-11-07T10:29:10Z"],["dc.date.available","2018-11-07T10:29:10Z"],["dc.date.issued","2017"],["dc.description.abstract","Background Obstruction is a common cause of ventriculoperitoneal shunt failure. Head computed tomography and plain x-ray examinations of shunt tubing (\"shunt series\") are routinely used in patients readmitted for reemerging symptoms but are of limited value. The validity of shunt series can be improved by applying contrast agent into the system (contrast-enhanced shunt series, a.k.a.a \"shuntogram\" or \"shuntography\"). We hypothesized that contrast-enhanced shunt series have a high predictive value for shunt revision surgeries. Methods We retrospectively re-evaluated 107 contrast-enhanced shunt series and reviewed the patient histories. We defined outcome parameters for calculating the utility of a pathological contrast-enhanced shunt series in predicting revision surgery. Results Of 107 contrast-enhanced shunt series, 41 examinations were positive for obstruction, mainly of the ventricular (36.5 %) and the peritoneal catheter (48.8 %). Within 30 days, 35 successful revision surgeries and 3 revision surgeries without resolution of symptoms were performed. In two cases the shunt tubing was found to be patent. Sixty-six negative examinations resulted in two revision surgeries, in addition to ten surgeries not attempting to restore patency. After 30 days, the specificity of contrast-enhanced shunt series for shunt failure identification was calculated at 92.8 %, the sensitivity at 94.7 %, the positive predictive value at 87.8 %, and the negative predictive value at 97.0 %. Conclusions The contrast-enhanced shunt series method is a highly specific examination with a negative predictive value exceeding that of head computed tomography and plain shunt series. Compared to radionuclide marker studies, contrastenhanced shunt series demonstrate better spatiotemporal resolution, enabling focused local surgical repair."],["dc.identifier.doi","10.1007/s00701-016-3007-x"],["dc.identifier.isi","000393022000012"],["dc.identifier.pmid","27817007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43586"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0942-0940"],["dc.relation.issn","0001-6268"],["dc.title","Contrast-enhanced shunt series (\"shuntography\") compare favorably to other shunt imaging modalities in detecting shunt occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","47"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","CANCER GENETICS AND CYTOGENETICS"],["dc.bibliographiccitation.lastpage","51"],["dc.bibliographiccitation.volume","198"],["dc.contributor.author","Gutenberg, Angelika"],["dc.contributor.author","Gerdes, Jan S."],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Sander, Bjoern"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Fuezesi, Laszlo"],["dc.date.accessioned","2018-11-07T08:44:22Z"],["dc.date.available","2018-11-07T08:44:22Z"],["dc.date.issued","2010"],["dc.description.abstract","Information on structural chromosomal changes in brain metastases (BM) of colorectal carcinoma (CRC) is very limited. Therapeutic and diagnostic strategies to reduce the risk of BM have potential impact on cancer mortality. By using comparative genomic hybridization, the primary CRC of 11 patients and their corresponding 13 BM were analyzed. BM showed significantly more mean chromosomal aberrations than the primary CRC (13.6 +/- 2.1 vs. 7.9 +/- 1.9, P = 0.03), significantly more chromosomal gains (7.2 +/- 0.9 vs. 3.5 +/- 0.9, P = 0.01), and tended to have also more losses (6.1 +/- 1.4 vs. 4.0 +/- 1.1, P = 0.29). Changes that occurred significantly more often in BM than in primary CRC were gains of 8q, 12p, 12q, and 20p, as well as losses of 5q. BM of CRC show a significantly higher chromosomal instability in comparison to primary tumors. The prevalently altered genomic regions in the metastases of this study are likely to harbor genes that play an important role in the genesis of brain-specific metastasis. (C) 2010 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.cancergencyto.2009.12.006"],["dc.identifier.isi","000276330200008"],["dc.identifier.pmid","20303014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20184"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0165-4608"],["dc.title","High chromosomal instability in brain metastases of colorectal carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]